FindTrial
Sign In

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT06004128
Enrollment
Unknown
Registered
2023-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Provide pre-approval single-patient Expanded Access (Compassionate Use) of VYD222 for patients with symptomatic COVID-19 refractory to other treatments.

Interventions

DRUGVYD222

Monoclonal antibody

Sponsors

Invivyd, Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026